TITLE

The Probable Source of Both the Primary Multidrug-Resistant (MDR) HIV-1 Strain Found in a Patient with Rapid Progression to AIDS and a Second Recombinant MDR Strain Found in a Chronically HIV-1—Infected Patient

AUTHOR(S)
Blick, Gary; Kagan, Ron M.; Coakley, Eoin; Petropoulos, Christos; Maroldo, Laura; Greiger-Zanlungo, Paola; Gretz, Scott; Garton, Trish
PUB. DATE
May 2007
SOURCE
Journal of Infectious Diseases;5/1/2007, Vol. 195 Issue 9, p1250
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Rapid progression to AIDS after acute infection with a multidrug-resistant (MDR), dual-tropic strain of human immunodeficiency virus type 1 (HIV-1) was reported in a New York City man (hereafter referred to as ‘NYC’) who has sex with men. The probable source of this HIV-1 (hereafter referred to as ‘CT01’) and the development of a recombinant MDR HIV-1 in the source's partner (hereafter referred to as ‘CT02’) are described. Methods. After identification of the epidemiological link of CT01 and CT02 to NYC, viral sequences and phenotypic analyses were compared. Confirmatory genotypic and phenotypic analyses, replicative capacity, and viral coreceptor use were assessed. Viral recombination was assessed using a sliding window technique and phylogenetic tree analysis. Results. NYC and CT01 were linked historically and epidemiologically and were genetically confirmed from CT01's samples acquired 2 days before and subsequent to the transmission event. Genotypic, recombination, and phylogenetic analyses suggest CT02 became superinfected by CT01 with subsequent production of a recombinant panresistant HIV-1. Conclusion. The probable source of a dual-tropic, MDR HIV-1 that was associated with rapid progression to AIDS is illustrated, suggesting progression was not explained by the HIV-1 variant alone. A probable second finding of a chronically infected host becoming superinfected with MDR HIV-1 with subsequent formation of a panresistant recombinant HIV-1 is described. This case illustrates the public health implications of unsafe sex between serodiscordant and seroconcordant partners.
ACCESSION #
24677989

 

Related Articles

  • The Epidemic Comes Home: b. The Ethical Dimension: "Don't Tell Me on Friday". Richards, Thomas // AIDS Reader (Branden Publishing);1988, p232 

    The article presents a reprint of the article "Don't Tell Me on Friday," by Thomas Richards, which appeared on the April 5, 1986 issue of the British Medical Journal. The author relates his experience on being positive for antibodies to human T cell lymphotropic virus III. He was shocked upon...

  • Crystalluria in HIV/AIDS patients on highly active anti-retro viral therapy in the Kumasi metropolis; a cross sectional study. Ephraim, Richard K. D.; Brenyah, Ruth C.; Osei, Richmond; Bossipe, Bright D.; Adoba, Prince; Osakunor, Derick N. M.; Agbodzakey, Hope // Nigerian Medical Journal;Nov/Dec2014, Vol. 55 Issue 6, p504 

    Background: Crystalluria is associated with some highly active anti-retroviral therapies (HAART's) used in the management of HIV/AIDS. Aims: This study used light microscopy to establish the prevalence of crystalluria among HIV/AIDS patients on HAART and identified the routine crystals present...

  • Aggressive HIV strain sets off dubious public health measure. Basu, Paroma // Nature Medicine;Apr2005, Vol. 11 Issue 4, p360 

    Reports on the controversy over a media report of a highly virulent and multidrug-resistant HIV strain. Scientists and activists' criticism against the New York City Department of Health and Mental Hygiene for prematurely inflating the significance of a single case of HIV; City health...

  • A retrospective review comparing treatment outcomes of adjuvant lung resection for drug-resistant tuberculosis in patients with and without human immunodeficiency virus co-infection. Alexandera, Gerard R.; Biccard, Bruce // European Journal of Cardio-Thoracic Surgery;Mar2016, Vol. 49 Issue 3, p823 

    OBJECTIVES: This review was undertaken to compare treatment outcomes in human immunodeficiency virus (HIV) negative versus HIVpositive patients following adjuvant lung resection for drug-resistant tuberculosis (DR-TB) in patients deemed feasible for surgery. Despite appropriate medical therapy,...

  • Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community. Andrews, Jason R.; Shah, N. Sarita; Weissman, Darren; Moll, Anthony P.; Friedland, Gerald; Gandhi, Neel R. // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Background: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) have emerged in high-HIVprevalence settings, which generally lack laboratory infrastructure for diagnosing TB drug resistance. Even where available, inherent delays with current drug-susceptibility...

  • Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. Grant, Philip; Taylor, Jonathan; Cain, Pat; Short, William; Gallant, Joel; Farthing, Charles; Thal, Gary; Coakley, Eoin; Zolopa, Andrew // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, p680 

    When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HIV)--infected patients who were randomized to receive atazanavir or boosted atazanavir, compared...

  • Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice. Gupta, R. K.; Loveday, Clive; Kalidindi, U.; Lechelt, M.; Skinner, Celia; Orkin, Chloe // International Journal of STD & AIDS;Sep2007, Vol. 18 Issue 9, p630 

    Escalating drug resistance in treatment-experienced HIV-1-infected patients has made management increasingly difficult. In clinical trials, tipranavir (TPV) has produced potent and durable responses in such patients, although experience in clinical cohorts is limited. A retrospective clinical...

  • Outcome of Multidrug-Resistant Tuberculosis in Human Immunodeficiency Virus-Infected Patients. Franzetti, Fabio; Gori, Andrea; Iemoli, Enrico; Meraviglia, Paola; Mainini, Franco; Quirino, Tizinia; degli Esposti, Anna; degl'Innocenti, Maura; Grassini, Anna; Nardi, Giampiero; Cargnel, Antonietta // Clinical Infectious Diseases;9/1/1999, Vol. 29 Issue 3, p553 

    Evaluates the variables influencing the span of time of survival in an HIV-positive population with tuberculosis and high levels of multiple drug resistance among HIV-infected persons. Significance of time delay between the onset of symptoms and start of therapy on survival time; Efficacy of...

  • Clues Emerge on How HIV Increases Lymphoma Risk. Brower, Vicki // JNCI: Journal of the National Cancer Institute;Jul2010, Vol. 102 Issue 14, p1002 

    The article examines studies on why people infected with human immunodeficiency virus (HIV) are at high risk for lymphoma. It gives details on a study which suggests that macrophages in AIDS-related lymphoma (ARL) patients could be a haven for HIV, allowing the virus to develop resistance to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics